Clinical trial
Mixed Antagonist of Serotonin for Claudication Optimal Therapy
NCT00300339 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00300339 |
|---|---|
| Title | Mixed Antagonist of Serotonin for Claudication Optimal Therapy |
| Official title | Double-Blind, Double-Dummy, Randomized, Parallel Group Trial of SL650472 (Three Dose Regimens Versus Placebo and Cilostazol), for 24-Week Improvement of Walking Distance in Patients With Stage II Peripheral Arterial Disease Who Benefit From Optimal Prevention Strategy Including Clopidogrel |
| Acronym | MASCOT |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Intermittent Claudication |
| Intervention type | Drug |
| Interventions | SL650472, Clopidogrel |
| Enrollment | 599 |
| Start date | Feb 1, 2006 |
| Primary completion | Dec 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Mar 8, 2006 |
| Last update posted | Dec 19, 2008 |
| Countries | Belgium, Canada, Czechia, Germany, Mexico, Russia, Sweden, Ukraine, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: